Rafferty Asset Management
TVRD

Rafferty Asset Management’s Tvardi Therapeutics TVRD Stock Holding History

Rafferty Asset Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-295
Closed -$97K – 1269
2022
Q2 		$97K Buy
+295
New +$103K ﹤0.01% 1074
2022
Q1 		– Sell
-394
Closed -$173K – 1339
2021
Q4 		$173K Buy
+394
New +$198K ﹤0.01% 1236
2019
Q3 		– Sell
-2,702
Closed -$2.09M – 857
2019
Q2 		$2.09M Buy
2,702
+393
+17% +$276K 0.04% 410
2019
Q1 		$1.63M Buy
+2,309
New +$1.38M 0.03% 453

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rafferty Asset Management's TVRD Position: Q3 2022 in Review

Rafferty Asset Management sold out of Tvardi Therapeutics (TVRD) in Q3 2022, closing a stake of 295 shares — an estimated $97K sold.

Rafferty Asset Management first reported a position in TVRD in Q1 2019 and held it in 4 quarters. The position peaked at $2.09M in Q2 2019. 165 funds tracked by Wall St. Rank hold TVRD as of Q3 2022.

  • Rafferty Asset Management reported no remaining Tvardi Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Rafferty Asset Management sold 295 Tvardi Therapeutics shares in Q3 2022, an estimated $97K.
  • Rafferty Asset Management first reported a position in Tvardi Therapeutics in Q1 2019 and held it in 4 quarters.
  • Rafferty Asset Management's Tvardi Therapeutics position peaked at $2.09M in Q2 2019.
  • 165 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2022.

Based on Rafferty Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.